SCHEMBL6480681

SCHEMBL6480681

CC(CNS(=O)(=O)C(C)C)Oc1ccc(-c2ccc(NC(=O)C(C)C)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIA4 P48058 7/20 0.48
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
GRIA2 P42262 2/20 0.43
MTNR1B P49286 2/20 0.41
ALDH1A1 P00352 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
MTNR1A P48039 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482776 0.89 GRIA4 (0.49) GRIA4CA12CA1CA2CA9
SCHEMBL6482318 0.85 GRIA4 (0.53) GRIA4GRIA2MTNR1BMAPTMTNR1A
SCHEMBL6480684 0.85 CA1 (0.41) GRIA4CA12CA1CA2CA9
SCHEMBL6475441 0.83 GRIA4 (0.42) GRIA4GRIA2MTNR1BALDH1A1MEN1
SCHEMBL6475284 0.82 GRIA4 (0.53) GRIA4CA12CA1CA2CA9
SCHEMBL6481825 0.81 GRIA4 (0.48) GRIA4CA12CA1CA2CA9
SCHEMBL6480644 0.81 GRIA4 (0.66) GRIA4MTNR1BMEN1KMT2AMTNR1A
SCHEMBL6482156 0.80 MTNR1A (0.52) GRIA4GRIA2MTNR1BMTNR1A
SCHEMBL6475291 0.80 GRIA4 (0.62) GRIA4GRIA2MTNR1BMAPTMTNR1A
SCHEMBL6474389 0.80 GRIA4 (0.62) GRIA4GRIA2MTNR1BALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US claimed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US claimed
EP-1265857-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-18 EP claimed
WO-2001068592-A1 SULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2001-09-20 WO claimed
US-6911476-B2 Sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-06-28 US disclosed
US-20030225266-A1 Sulfonamide derivatives ELI LILLY AND COMPANY 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225266-A1 Sulfonamide derivatives GRIN2A, GRM2, GRIA2 GRIA4 6/4885CA12 2263/4885CA1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.